Adenoviral Vector for Enhanced Prostate Cancer Specific Transferrin Conjugated Drug Targeted Therapy,Nano Letters

当前位置： X-MOL 学术 › Nano Lett. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Adenoviral Vector for Enhanced Prostate Cancer Specific Transferrin Conjugated Drug Targeted Therapy
Nano Letters ( IF 9.6 ) Pub Date : 2022-05-06 , DOI: 10.1021/acs.nanolett.2c00931
Jing Peng _{1,

2} , Kangkang Liu _{3,

4} , Lin Cao ₁ , Dengyi Duan ₁ , Guodong Song ₅ , Shuang Liu ₁ , Lining Wang ₃ , Jianmin Li ₃ , Xuening Zhang ₁ , Kai Huang ₂ , Yang Zhao _{1,

2,

3} , Yuanjie Niu _{3,

4} , Gang Han ₂

Affiliation

Prostate cancer (PCa) is one of the leading causes of death for men worldwide. Unlike some other types of cancer, there is a lack of targeted therapy for prostate cancer patients that can kill cancer cells but do much less damage to the normal tissue. In this paper, we report on an adenoviral vector enhanced prostate cancer specific transferrin conjugated drug targeted therapy. In particular, a functional PCa-specific gene probe is introduced to drive and up-regulate the transferrin receptor expression on the PCa via adenoviral vector. As a result, significantly enhanced accumulation of nanoscale transferrin-doxorubicin (Tf-DOX) protein drug conjugates and concomitant notably elevated PCa tumor inhibition are observed. This conceptual strategy provides the proof-of-concept for the targeted therapy of PCa that is highly desired but not yet developed.

中文翻译：

用于增强前列腺癌特异性转铁蛋白偶联药物靶向治疗的腺病毒载体

前列腺癌 (PCa) 是全球男性死亡的主要原因之一。与某些其他类型的癌症不同，前列腺癌患者缺乏可以杀死癌细胞但对正常组织造成的损害要小得多的靶向治疗。在本文中，我们报告了腺病毒载体增强的前列腺癌特异性转铁蛋白偶联药物靶向治疗。特别是，引入功能性 PCa 特异性基因探针，通过腺病毒载体驱动和上调 PCa 上的转铁蛋白受体表达。结果，观察到纳米级转铁蛋白-多柔比星 (Tf-DOX) 蛋白药物偶联物的积累显着增强，并且伴随着显着升高的 PCa 肿瘤抑制。

更新日期：2022-05-06

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南